The Safety & Tolerability of INP104 is Currently Being Evaluated in the Company’s Recently Fully-Enrolled Pivotal Phase 3 “STOP-301” Trial New Data from a Patient Experience Survey Describe Dissatisfaction Levels with Current Available Treatments & Desire for New Options That Offer More Rapid & Complete Relief of Migraine Symptoms with a Lower Side Effect Profile SEATTLE, September...

DHE is effective for acute migraine. The approved label warns of potential cardiovascular effects although the clinical experience of DHE over 70 years of use has been good. Work has shown the high Cmax of IV DHE may account for increased pulmonary arterial systolic pressure through increased adrenergic receptor binding....

Dihydroergotamine mesylate was approved in 1946 for the treatment of migraine and for the next 40 years was available as the most specific, acute anti-migraine therapy until the advent of the Triptans. DHE is still used today, available in multiple formulations and remains a dependable choice for Neurologists and Headache...

Migraine is a common, disabling disorder. IV DHE is an effective abortive therapy; however, the nasal formulation, Migranal®, has poor bioavailability and variable efficacy. We found INP104 (1.45 mg DHE) to have 4X greater systemic exposure than Migranal (2 mg) as a result of delivery technology4. In INP104, the POD...

Poster presented at World Parkinson's Congress 2019 in Kyoto, Japan Authors: Shrewsbury SB, Campbell J, Swardstrom M, Lehn A, Satterly KH, Hoekman J Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuated Precision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid systemic uptake and higher bioavailability relative to standard nasal sprays. This study with L-dopa for treatment of morning...

A patient-friendly, self or caregiver actuated device to achieve consistent upper nasal space drug delivery, rapid systemic uptake and higher bioavailability than standard nasal sprays. The Quantitative Scoring Scale – Nasal Mucosa (QSS-NM) was developed, at FDA request, as a physician-administered major component of a comprehensive nasal assessment. ...

An estimated 1.7 million acute agitation events occur annually; OLZ IM is a preferred option due to a shorter Tmax than oral, but IM administration, predominantly administered in a hospital setting, can be painful, humiliating, invasive, and requires cooperation or restraint which reduces trust, increases healthcare worker injuries and may...

SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Nearing...